<HashMap><database>biostudies-other</database><scores/><additional><submitter>Chung JO</submitter><funding>NICHD NIH HHS</funding><funding>NCRR NIH HHS</funding><funding>NIDDK NIH HHS</funding><pagination>2082-2091</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5521869</full_dataset_link><abstract>We investigated the relationship between insulin resistance markers and subsarcolemmal (SS) and intramyofibrillar (IMF) ceramide concentrations, as well as the contribution of plasma palmitate (6.5-h infusion of [U-13C]palmitate) to intramyocellular ceramides. Seventy-six postabsorptive men and women had muscle biopsies 1.5, 6.5, and 24 h after starting the tracer infusion. Concentrations and enrichment of muscle ceramides were measured by liquid chromatography-tandem mass spectrometry. We found that HOMA of insulin resistance, plasma insulin, and triglyceride concentrations were positively correlated with SS C16:0 and C18:1 ceramide, but not SS C14:0-Cer, C20:0-Cer, C24:0-Cer, and C24:1-Cer concentrations; IMF ceramide concentrations were not correlated with any metabolic parameters. The fractional contribution of plasma palmitate to 16:0 ceramide was greater in SS than IMF (SS, 18.2% vs. IMF, 8.7%; P = 0.0006). Plasma insulin concentrations correlated positively with the fractional contribution of plasma palmitate to SS 16:0 ceramide. The fractional contribution of plasma palmitate to intramyocellular SS 16:0 ceramide was positively correlated with SS C16:0 ceramide concentrations (? = 0.435; P = 0.002). We conclude that skeletal muscle SS ceramides, especially C16 to C18 chain lengths and the de novo synthesis of intramyocellular ceramide from plasma palmitate are associated with markers of insulin resistance.</abstract><repository>biostudies-other</repository><data_source>Europe PMC</data_source><omics_type>Unknown</omics_type><volume>66(8)</volume><journal>Diabetes</journal><pmcid>PMC5521869</pmcid><funding_grant_id>R01 DK045343</funding_grant_id><funding_grant_id>T32 DK007352</funding_grant_id><funding_grant_id>K12 HD065987</funding_grant_id><funding_grant_id>P30 DK050456</funding_grant_id><funding_grant_id>M01 RR000585</funding_grant_id><funding_grant_id>R01 DK040484</funding_grant_id><funding_grant_id>R37 DK040484</funding_grant_id><pubmed_authors>Hames KC</pubmed_authors><pubmed_authors>Blachnio-Zabielska AU</pubmed_authors><pubmed_authors>Jensen MD</pubmed_authors><pubmed_authors>Chung JO</pubmed_authors><pubmed_authors>Koutsari C</pubmed_authors></additional><is_claimable>false</is_claimable><name>Intramyocellular Ceramides: Subcellular Concentrations and Fractional De Novo Synthesis in Postabsorptive Humans.</name><description>We investigated the relationship between insulin resistance markers and subsarcolemmal (SS) and intramyofibrillar (IMF) ceramide concentrations, as well as the contribution of plasma palmitate (6.5-h infusion of [U-13C]palmitate) to intramyocellular ceramides. Seventy-six postabsorptive men and women had muscle biopsies 1.5, 6.5, and 24 h after starting the tracer infusion. Concentrations and enrichment of muscle ceramides were measured by liquid chromatography-tandem mass spectrometry. We found that HOMA of insulin resistance, plasma insulin, and triglyceride concentrations were positively correlated with SS C16:0 and C18:1 ceramide, but not SS C14:0-Cer, C20:0-Cer, C24:0-Cer, and C24:1-Cer concentrations; IMF ceramide concentrations were not correlated with any metabolic parameters. The fractional contribution of plasma palmitate to 16:0 ceramide was greater in SS than IMF (SS, 18.2% vs. IMF, 8.7%; P = 0.0006). Plasma insulin concentrations correlated positively with the fractional contribution of plasma palmitate to SS 16:0 ceramide. The fractional contribution of plasma palmitate to intramyocellular SS 16:0 ceramide was positively correlated with SS C16:0 ceramide concentrations (? = 0.435; P = 0.002). We conclude that skeletal muscle SS ceramides, especially C16 to C18 chain lengths and the de novo synthesis of intramyocellular ceramide from plasma palmitate are associated with markers of insulin resistance.</description><dates><release>2017-01-01T00:00:00Z</release><publication>2017 Aug</publication><modification>2019-03-26T23:48:32Z</modification><creation>2019-03-26T23:48:32Z</creation></dates><accession>S-EPMC5521869</accession><cross_references><pubmed>28483801</pubmed><doi>10.2337/db17-0082 </doi></cross_references></HashMap>